Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the U.S. – his administration’s bid to boost ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is ...

CEOs have been grilled on tariffs and their impact on business and consumers' wallets in recent earnings calls and interviews ...

Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed tariffs on imported medicines is ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...